Stay updated on FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.

Latest updates to the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page
- Check4 days agoChange DetectedThe version/release label at the bottom of the page was updated from Revision: v3.5.0 to Revision: v3.5.3.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedLocation in Italy updated from Padua to Padova (35128); the Padova site is now listed and the Padua listing removed.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No changes to study data or page layout.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; this seems to be a small internal site update with no visible changes to study content.SummaryDifference0.0%

- Check76 days agoChange DetectedGastric cancer added as a related topic/keyword and Genetic and Rare Diseases Information Center resources linked; the page revision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedRevision label on the page updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.